CD274 and neoplasm: Using an orthotopic Pan02 tumor mouse model, combining the CD40 agonist (3 mg/kg on day 7, 14, 21, 28; clone FGK4.5) with PD-L1 blockade (10 mg/kg on day 7, 10, 14, 17, 21, 24; clone 10F.9G2) improved OS versus monotherapy with either agent.